Global Naloxone Spray market is valued at USD 380 Million in 2022 and is projected to attain a value of USD 1.4 Billion by 2030 at a CAGR of 19.90% during the forecast period, 2022–2028.
Naloxone Spray is used to treat opioid overdose symptoms such as respiratory issues, extreme tiredness, and inability to respond. Naloxone Spray is used to temporarily reverse the effects of opioid medications. People who have never been exposed to opioid drugs are unaffected by the medicine in this nasal Spray. After administering the first dose of nasal spray, the patient requires immediate medical attention. Approximately 400,000 people died as a result of an opioid overdose between 1999 and 2017, according to the Centers for Disease Control and Prevention. In addition, approximately 130 people die in America every day as a result of opioid overdoses, which include prescription pharmaceuticals such as oxycodone, fentanyl, morphine, and hydrocodone, as well as illegal substances such as heroin or drugs sold as heroin.
Naloxone Spray Market Size, 2022 To 2030 (USD Billion)
Launches and Approval of New Spray
Increased launches and approvals of novel Naloxone Spray products are expected to be a major factor in the market's growth in the future years. Pfizer, a large pharmaceutical manufacturer, for example, announced a generic naloxone nasal spray in April 2020, which is projected to dramatically boost market demand. In addition, as the number of opioid overdoses rises, efforts are being made to make this emergency overdose reversal drug more readily available and accessible to those who may need it. The FDA has also taken the extraordinary step of supporting manufacturers in obtaining FDA approval for an over-the-counter Naloxone Spray product, and is looking into other options to expand the availability of naloxone medicines for community usage.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Legal Status and Availability to Law Enforcement and Emergency Personnel
There are a number of limits and limitations that will limit market expansion. With the exception of Hawaii, naloxone is apparently available without a prescription in every state in the United States. In actuality, not all pharmacies have naloxone on hand or can dispense it. Because naloxone is still considered a prescription-only drug under FDA standards, a pharmacist may be required to write a prescription or may not be permitted to administer it, depending on the pharmacy. As naloxone is a fairly new product, the high cost associated with this product coupled with the serious side-effects may create hindrances in the market growth.
The Global Naloxone Spray Market can be segmented by Dosage into 2 mg/actuation and 4 mg/actuation. Based on Distribution Channel into, Hospitals, Clinics, Retail, Pharmacies, Online Pharmacies and Others. Based on Region, the Naloxone Spray Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Naloxone Spray Market
In 2021, North America held the greatest proportion of the global market for Naloxone Spray, followed by Europe. The United States is the largest market in North America, with high rates of opioid overdose and an increasing number of victims addicted to opioids and morphine. Furthermore, the country is in the midst of an epidemic, as the number of deaths increased by 21% in 2016. In 2017, the US Federal Government declared the opioid crisis a Public Health Emergency, which is projected to fuel future market growth. Teva Pharmaceutical Industries Ltd. was given approval by the US Food and Drug Administration on Friday to launch generic naloxone nasal spray to treat opioid overdoses in April 2020.
USD 0.50 Billion
Major players operating in the global Naloxone Spray, market include Emergent BioSolutions (US), Pfizer (US), Teva Pharmaceutical Industries Ltd. (Israel), Opiant Pharmaceuticals (US), Hikma Pharmaceuticals (UK), Nasus Pharma (Israel), Amphastar Pharmaceuticals (US), Indivior PLC (US), Samarth Pharma Pvt. Ltd. (India), Troikaa Pharmaceuticals Ltd. (India), and Neon Laboratories Limited (India).
The Naloxone Spray market is segmented as follows:
- Dosage (2 mg/actuation, 4 mg/actuation, Others)
- Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Others)
- Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Emergent BioSolutions (US)
- Pfizer (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Opiant Pharmaceuticals (US)
- Hikma Pharmaceuticals (UK)
- Nasus Pharma (Israel)
- Amphastar Pharmaceuticals (US)
- Indivior PLC (US)
- Samarth Pharma Pvt. Ltd. (India)
- Troikaa Pharmaceuticals Ltd. (India)
- and Neon Laboratories Limited (India).
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options